URL | https://www.fiercepharma.com/manufacturing/beigene |
Source | https://www.fiercepharma.com |
Date Published | 11/24/2021 |
Author Name | Joseph Keenan |
Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
Company/Division name | BeiGene Ltd. |
Parent company | BeiGene |
Type of work | Manufacturing |
Reshoring category: | Foreign Direct Investment |
What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
Year reshoring announced: | 2021 |
Year reshoring implemented or to be implemented: | 2024 |
Domestically, the work will be done: | In-house |
Country(ies) from which reshored: | China |
State(s) reshored to: | NJ |
If relevant, work nearshored to: | - |
Industry(ies): | Chemicals, Cancer drugs |
Product(s) reshored | Cancer drugs |